Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 1464
Special Issue Editors
Interests: Alpha-synuclein; Synapsin III; Parkinson’s disease; Dopaminergic synapses; protein aggregation; fibrillation; small molecules
Interests: drug discovery; medicinal chemistry, structure activity relationship; development of novel antimicrobials; FtsZ inhibitors; RnpA inhibitors; inhibition of bacterial cellular division process
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases are a heterogeneous group of disorders characterized by the progressive loss of neurons in the central or peripheral nervous system and can present different symptomatologic manifestations mainly affecting cognition and motility. Among them, the most common age-associated disorders are Alzheimer’s disease and Parkinson’s disease, followed by conditions with lower incidence such as Frontotemporal Lobar degeneration (FTLD) syndromes, Lewy Body dementia, Amyotrophic Lateral Sclerosis, Multiple system Atrophy, Huntington’s disease. A main common neuropathological feature of most of these syndromes is the progressive deposition of pathological protein aggregates that is considered to play a main causative role in onset and worsening of these disorders.
In the last two decades, the number of people living with neurodegenerative disorders has raised due to increased aging of world population, and their social and economic burden has become a major health issue. This notwithstanding, despite the great efforts dedicated to the identification new therapeutic targets and development of innovative disease-modifying agents, we still miss effective approaches able to halt or delay symptom progression and neurodegeneration in the brain of patients affected by these highly disabling conditions.
The aim of this Special Issue is to collect the latest research on novel therapeutic targets, as well as innovative deliveries or formulations, for the design and pharmacological characterization of disease-modifying agents, counteracting neuronal loss, exerting neuroprotection or reducing pathological protein aggregates in neurodegenerative diseases.
Dr. Francesca Longhena
Dr. Valentina Straniero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- frontotemporal lobar degeneration syndromes
- amyotrophic lateral sclerosis
- multple system Atrophy
- lewy body dementia
- synucleinopathies
- Pick’s disease
- corticobasal degeneration
- protein aggregates
- disease-modifying therapies
- treatment
- neuroprotection
